Search research articles
Contact Us
Filters
Showing results (81-90 of 93) with videos related to
Page
of 10
Sort By:
Antimicrobial Resistance and Infection Control
|
March 19, 2021
Investigating potential transmission of antimicrobial resistance in an open-plan hospital ward: a cross-sectional metagenomic study of resistome dispersion in a lower middle-income setting
Anushia Ashokan, Josh Hanson, Ne Myo Aung, et al.
The Lancet. HIV
|
October 2, 2015
Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis
Mark A Boyd, Cecilia L Moore, Jean-Michel Molina, et al.
Plos One
|
October 10, 2015
Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection
Janaki Amin, Mark A Boyd, Nagalingeswaran Kumarasamy, et al.
Plos Medicine
|
November 8, 2017
Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study
Mark A Boyd, Amanda Mocroft, Lene Ryom, et al.
Plos One
|
February 28, 2015
Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection
Janaki Amin, Mark A Boyd, Nagalingeswaran Kumarasamy, et al.
Sexually Transmitted Diseases
|
May 19, 2020
Factors Associated With Early Resumption of Condomless Anal Sex Among Men Who Have Sex With Men After Rectal Chlamydia Treatment
Andrew Lau, Fabian Y S Kong, Christopher K Fairley, et al.
The Lancet. HIV
|
November 6, 2016
Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study
Mark A Boyd, Janaki Amin, Patrick W G Mallon, et al.
European Journal of Gastroenterology & Hepatology
|
January 3, 2020
Cost effectiveness of treatment models of care for hepatitis C: the South Australian state-wide experience
Jeyamani Ramachandran, Billingsley Kaambwa, Kate Muller, et al.
BMC Infectious Diseases
|
November 18, 2025
A point-of-care testing intervention to improve hepatitis C diagnosis and treatment uptake among people attending Aboriginal community controlled health services: the SCALE-C study
Samira Hosseini-Hooshyar, Heather Valerio, Erin Flynn, et al.
Frontiers in Public Health
|
October 9, 2023
Exploring self-determined solutions to service and system challenges to promote social and emotional wellbeing in Aboriginal and Torres Strait Islander people: a qualitative study
Anna P Dawson, Eugene Warrior, Odette Pearson, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 93) with videos related to
Sort By:
Page
of 10
Antimicrobial Resistance and Infection Control
|
March 19, 2021
Investigating potential transmission of antimicrobial resistance in an open-plan hospital ward: a cross-sectional metagenomic study of resistome dispersion in a lower middle-income setting
Anushia Ashokan, Josh Hanson, Ne Myo Aung, et al.
The Lancet. HIV
|
October 2, 2015
Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis
Mark A Boyd, Cecilia L Moore, Jean-Michel Molina, et al.
Plos One
|
October 10, 2015
Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection
Janaki Amin, Mark A Boyd, Nagalingeswaran Kumarasamy, et al.
Plos Medicine
|
November 8, 2017
Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study
Mark A Boyd, Amanda Mocroft, Lene Ryom, et al.
Plos One
|
February 28, 2015
Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection
Janaki Amin, Mark A Boyd, Nagalingeswaran Kumarasamy, et al.
Sexually Transmitted Diseases
|
May 19, 2020
Factors Associated With Early Resumption of Condomless Anal Sex Among Men Who Have Sex With Men After Rectal Chlamydia Treatment
Andrew Lau, Fabian Y S Kong, Christopher K Fairley, et al.
The Lancet. HIV
|
November 6, 2016
Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study
Mark A Boyd, Janaki Amin, Patrick W G Mallon, et al.
European Journal of Gastroenterology & Hepatology
|
January 3, 2020
Cost effectiveness of treatment models of care for hepatitis C: the South Australian state-wide experience
Jeyamani Ramachandran, Billingsley Kaambwa, Kate Muller, et al.
BMC Infectious Diseases
|
November 18, 2025
A point-of-care testing intervention to improve hepatitis C diagnosis and treatment uptake among people attending Aboriginal community controlled health services: the SCALE-C study
Samira Hosseini-Hooshyar, Heather Valerio, Erin Flynn, et al.
Frontiers in Public Health
|
October 9, 2023
Exploring self-determined solutions to service and system challenges to promote social and emotional wellbeing in Aboriginal and Torres Strait Islander people: a qualitative study
Anna P Dawson, Eugene Warrior, Odette Pearson, et al.
Page
of 10